Potential Role of Cuproptosis-Related Lncrna in Prognosis and Immunotherapy of Thyroid Carcinoma
-
Yunying Cai
,
Ben Niu
,
Jie Gao
,
Heng Su
Abstract
Background: Cuproptosis-related long non-coding RNA (lncRNA) disease is associated with the development and progression of tumors. We aimed to investigate the prediction of cuproptosis-related lncRNA on the prognosis and immunotherapy of patients with thyroid carcinoma (THCA).
Methods: The thyroid cancer-associated expression data and lnc RNAs data were downloaded from The Cancer Genome Atlas (TCGA) and Ensembl database. The prognostic model of cuproptosis-related lncRNAs was successfully constructed through Lasso regression analysis and Cox regression analysis. Then, the prognostic value of prognostic model of cuproptosis-related lncRNAs was tested through the survival analysis, ROC curves and nomographic charts. Finally, the prognostic model of cuproptosis-related lncRNAs associated with immunity and mutational load of tumors was analyzed, and potential targeted drugs for THCA were predicted.
Results: A cuproptosis-related lncRNA model of THCA (AC026100.1, AF235103.3, LNCSRLR) was successfully constructed, which has an independent prognostic value. Moreover, the cuproptosis-related lncRNA model was associated with immune signatures and mutational load in most tumors, showing its high correlation with the sensitivity of targeted drugs such as 5-Fluorouracil, Bleomycin, Rapamycin and Sunitinib.
Conclusion: The cuproptosis-related lncRNA model of THCA has promising applications in the treatment and prognosis of THCA.
1. Ho AL, Dedecjus M, Wirth LJ, et al (2022). Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differ-entiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA). J Clin Oncol, 40(17):1870-1878.
2. Franchini F, Palatucci G, Colao A, Ungaro P, Macchia PE, Nettore IC (2022). Obesi-ty and Thyroid Cancer Risk: An Update. Int J Environ Res Public Health, 19(3):1116.
3. Pizzato M, Li M, Vignat J, et al (2022). The epidemiological landscape of thyroid can-cer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol, 10(4):264-272.
4. Nguyen M, He G, Lam AK (2022). Clinico-pathological and Molecular Features of Secondary Cancer (Metastasis) to the Thyroid and Advances in Management. Int J Mol Sci, 23(6):3242.
5. Rossi ED, Pantanowitz L, Hornick JL (2021). A worldwide journey of thyroid cancer incidence centred on tumour his-tology. Lancet Diabetes Endocrinol, 9(4):193-194.
6. Canadas-Garre M, Becerra-Massare P, Lopez de la Torre-Casares M, et al (2012). Reduction of false-negative papil-lary thyroid carcinomas by the routine analysis of BRAF(T1799A) mutation on fine-needle aspiration biopsy specimens: a prospective study of 814 thyroid FNAB patients. Ann Surg, 255(5):986-992.
7. Ha EJ, Na DG, Baek JH, Sung JY, Kim JH, Kang SY (2018). US Fine-Needle Aspira-tion Biopsy for Thyroid Malignancy: Di-agnostic Performance of Seven Society Guidelines Applied to 2000 Thyroid Nodules. Radiology, 287(3):893-900.
8. Filetti S, Durante C, Hartl DM, et al (2022). ESMO Clinical Practice Guideline update on the use of systemic therapy in ad-vanced thyroid cancer. Ann Oncol, 33(7):674-684.
9. Kebebew E (2022). Treatment for Advanced and Metastatic Thyroid Cancer Refractory to Standard Treatment-We Need to Know the When, What, and Who. JAMA Oncol, 8(2):250-251.
10. Tsvetkov P, Coy S, Petrova B, et al (2022). Copper induces cell death by targeting lipoylated TCA cycle proteins. Science, 375(6586):1254-1261.
11. Lin RX, Yang SL, Jia Y, Wu JC, Xu Z, Zhang H (2022). Epigenetic regulation of papillary thyroid carcinoma by long non-coding RNAs. Semin Cancer Biol, 83:253-260.
12. Ndika J, Karisola P, Kinaret P, Ilves M, Ale-nius H (2021). Profiling Non-Coding RNA Changes Associated with 16 Dif-ferent Engineered Nanomaterials in a Mouse Airway Exposure Model. Cells, 2021;10(5).
13. Yang M, Huang W, Sun Y, et al (2019). Prognosis and modulation mechanisms of COMMD6 in human tumours based on expression profiling and comprehen-sive bioinformatics analysis. Br J Cancer, 121(8):699-709.
14. Zhang R, Niu Z, Pei H, Peng Z (2020). Long noncoding RNA LINC00657 in-duced by SP1 contributes to the non-small cell lung cancer progression through targeting miR-26b-5p/COMMD8 axis. J Cell Physiol, 235(4):3340-3349.
15. Zhang H, Duan HL, Wang S, Liu Y, Ding GN, Lin RX (2022). Epigenetic signature associated with thyroid cancer progres-sion and metastasis. Semin Cancer Biol, 83:261-268.
16. Yoo SK, Song YS, Lee EK, et al (2019). In-tegrative analysis of genomic and tran-scriptomic characteristics associated with progression of aggressive thyroid cancer. Nat Commun, 10(1):2764.
17. Pu M, Messer K, Davies SR, et al (2020). Re-search-based PAM50 signature and long-term breast cancer survival. Breast Cancer Res Treat, 179(1):197-206.
18. Muller DC, Johansson M, Brennan P (2017). Lung Cancer Risk Prediction Model Incorporating Lung Function: Development and Validation in the UK Biobank Prospective Cohort Study. J Clin Oncol, 35(8):861-869.
19. Meurer WJ, Tolles J (2017). Logistic Regres-sion Diagnostics: Understanding How Well a Model Predicts Outcomes. JAMA, 317(10):1068-1069.
20. Ellahham S (2020). Artificial Intelligence: The Future for Diabetes Care. Am J Med, 133(8):895-900.
21. Andaur Navarro CL, Damen JAA, Takada T, et al (2021). Risk of bias in studies on prediction models developed using su-pervised machine learning techniques: systematic review. BMJ, 375:n2281.
22. Menicali E, Guzzetti M, Morelli S, Moretti S, Puxeddu E (2020). Immune Landscape of Thyroid Cancers: New Insights. Front Endocrinol (Lausanne), 11:637826.
23. Bian Z, Fan R, Xie L (2022). A Novel Cu-proptosis-Related Prognostic Gene Sig-nature and Validation of Differential Ex-pression in Clear Cell Renal Cell Carci-noma. Genes (Basel),13(5):851.
24. Shen Y, Peng X, Shen C (2020). Identifica-tion and validation of immune-related lncRNA prognostic signature for breast cancer. Genomics, 112(3):2640-2646.
25. Wu Z, Lu Z, Li L, et al (2021). Identification and Validation of Ferroptosis-Related LncRNA Signatures as a Novel Prognos-tic Model for Colon Cancer. Front Immu-nol, 12:783362.
26. Chen F, Yang J, Fang M, Wu Y, Su D, Sheng Y (2022). Necroptosis-related lncRNA to establish novel prognostic signature and predict the immunotherapy response in breast cancer. J Clin Lab Anal, 36(4):e24302.
27. Liu X, Wang D, Han S, et al (2022). Signa-ture of m5C-Related lncRNA for Prog-nostic Prediction and Immune Respons-es in Pancreatic Cancer. J Oncol, 2022:7467797.
28. Cai J, Ji Z, Wu J, et al (2022). Development and validation of a novel endoplasmic re-ticulum stress-related lncRNA prognostic signature and candidate drugs in breast cancer. Front Genet, 13:949314.
29. Lu H, Wu J, Liang L, Wang X, Cai H (2022). Identifying a Novel Defined Pyroptosis-Associated Long Noncoding RNA Sig-nature Contributes to Predicting Progno-sis and Tumor Microenvironment of Bladder Cancer. Front Immunol, 13:803355.
30. Scheiber I, Dringen R, Mercer JF (2013). Copper: effects of deficiency and over-load. Met Ions Life Sci, 13:359-387.
31. Cobine PA, Brady DC (2022). Cuproptosis: Cellular and molecular mechanisms un-derlying copper-induced cell death. Mol Cell, 82(10):1786-1787.
32. Ge EJ, Bush AI, Casini A, et al (2022). Con-necting copper and cancer: from transi-tion metal signalling to metalloplasia. Nat Rev Cancer, 22(2):102-113.
33. Kargozar S, Mozafari M, Ghodrat S, Fiume E, Baino F (2021). Copper-containing bi-oactive glasses and glass-ceramics: From tissue regeneration to cancer therapeutic strategies. Mater Sci Eng C Mater Biol Appl, 121:111741.
34. Subbiah V, Shen T, Terzyan SS, et al (2021). Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann On-col, 32(2):261-268.
2. Franchini F, Palatucci G, Colao A, Ungaro P, Macchia PE, Nettore IC (2022). Obesi-ty and Thyroid Cancer Risk: An Update. Int J Environ Res Public Health, 19(3):1116.
3. Pizzato M, Li M, Vignat J, et al (2022). The epidemiological landscape of thyroid can-cer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol, 10(4):264-272.
4. Nguyen M, He G, Lam AK (2022). Clinico-pathological and Molecular Features of Secondary Cancer (Metastasis) to the Thyroid and Advances in Management. Int J Mol Sci, 23(6):3242.
5. Rossi ED, Pantanowitz L, Hornick JL (2021). A worldwide journey of thyroid cancer incidence centred on tumour his-tology. Lancet Diabetes Endocrinol, 9(4):193-194.
6. Canadas-Garre M, Becerra-Massare P, Lopez de la Torre-Casares M, et al (2012). Reduction of false-negative papil-lary thyroid carcinomas by the routine analysis of BRAF(T1799A) mutation on fine-needle aspiration biopsy specimens: a prospective study of 814 thyroid FNAB patients. Ann Surg, 255(5):986-992.
7. Ha EJ, Na DG, Baek JH, Sung JY, Kim JH, Kang SY (2018). US Fine-Needle Aspira-tion Biopsy for Thyroid Malignancy: Di-agnostic Performance of Seven Society Guidelines Applied to 2000 Thyroid Nodules. Radiology, 287(3):893-900.
8. Filetti S, Durante C, Hartl DM, et al (2022). ESMO Clinical Practice Guideline update on the use of systemic therapy in ad-vanced thyroid cancer. Ann Oncol, 33(7):674-684.
9. Kebebew E (2022). Treatment for Advanced and Metastatic Thyroid Cancer Refractory to Standard Treatment-We Need to Know the When, What, and Who. JAMA Oncol, 8(2):250-251.
10. Tsvetkov P, Coy S, Petrova B, et al (2022). Copper induces cell death by targeting lipoylated TCA cycle proteins. Science, 375(6586):1254-1261.
11. Lin RX, Yang SL, Jia Y, Wu JC, Xu Z, Zhang H (2022). Epigenetic regulation of papillary thyroid carcinoma by long non-coding RNAs. Semin Cancer Biol, 83:253-260.
12. Ndika J, Karisola P, Kinaret P, Ilves M, Ale-nius H (2021). Profiling Non-Coding RNA Changes Associated with 16 Dif-ferent Engineered Nanomaterials in a Mouse Airway Exposure Model. Cells, 2021;10(5).
13. Yang M, Huang W, Sun Y, et al (2019). Prognosis and modulation mechanisms of COMMD6 in human tumours based on expression profiling and comprehen-sive bioinformatics analysis. Br J Cancer, 121(8):699-709.
14. Zhang R, Niu Z, Pei H, Peng Z (2020). Long noncoding RNA LINC00657 in-duced by SP1 contributes to the non-small cell lung cancer progression through targeting miR-26b-5p/COMMD8 axis. J Cell Physiol, 235(4):3340-3349.
15. Zhang H, Duan HL, Wang S, Liu Y, Ding GN, Lin RX (2022). Epigenetic signature associated with thyroid cancer progres-sion and metastasis. Semin Cancer Biol, 83:261-268.
16. Yoo SK, Song YS, Lee EK, et al (2019). In-tegrative analysis of genomic and tran-scriptomic characteristics associated with progression of aggressive thyroid cancer. Nat Commun, 10(1):2764.
17. Pu M, Messer K, Davies SR, et al (2020). Re-search-based PAM50 signature and long-term breast cancer survival. Breast Cancer Res Treat, 179(1):197-206.
18. Muller DC, Johansson M, Brennan P (2017). Lung Cancer Risk Prediction Model Incorporating Lung Function: Development and Validation in the UK Biobank Prospective Cohort Study. J Clin Oncol, 35(8):861-869.
19. Meurer WJ, Tolles J (2017). Logistic Regres-sion Diagnostics: Understanding How Well a Model Predicts Outcomes. JAMA, 317(10):1068-1069.
20. Ellahham S (2020). Artificial Intelligence: The Future for Diabetes Care. Am J Med, 133(8):895-900.
21. Andaur Navarro CL, Damen JAA, Takada T, et al (2021). Risk of bias in studies on prediction models developed using su-pervised machine learning techniques: systematic review. BMJ, 375:n2281.
22. Menicali E, Guzzetti M, Morelli S, Moretti S, Puxeddu E (2020). Immune Landscape of Thyroid Cancers: New Insights. Front Endocrinol (Lausanne), 11:637826.
23. Bian Z, Fan R, Xie L (2022). A Novel Cu-proptosis-Related Prognostic Gene Sig-nature and Validation of Differential Ex-pression in Clear Cell Renal Cell Carci-noma. Genes (Basel),13(5):851.
24. Shen Y, Peng X, Shen C (2020). Identifica-tion and validation of immune-related lncRNA prognostic signature for breast cancer. Genomics, 112(3):2640-2646.
25. Wu Z, Lu Z, Li L, et al (2021). Identification and Validation of Ferroptosis-Related LncRNA Signatures as a Novel Prognos-tic Model for Colon Cancer. Front Immu-nol, 12:783362.
26. Chen F, Yang J, Fang M, Wu Y, Su D, Sheng Y (2022). Necroptosis-related lncRNA to establish novel prognostic signature and predict the immunotherapy response in breast cancer. J Clin Lab Anal, 36(4):e24302.
27. Liu X, Wang D, Han S, et al (2022). Signa-ture of m5C-Related lncRNA for Prog-nostic Prediction and Immune Respons-es in Pancreatic Cancer. J Oncol, 2022:7467797.
28. Cai J, Ji Z, Wu J, et al (2022). Development and validation of a novel endoplasmic re-ticulum stress-related lncRNA prognostic signature and candidate drugs in breast cancer. Front Genet, 13:949314.
29. Lu H, Wu J, Liang L, Wang X, Cai H (2022). Identifying a Novel Defined Pyroptosis-Associated Long Noncoding RNA Sig-nature Contributes to Predicting Progno-sis and Tumor Microenvironment of Bladder Cancer. Front Immunol, 13:803355.
30. Scheiber I, Dringen R, Mercer JF (2013). Copper: effects of deficiency and over-load. Met Ions Life Sci, 13:359-387.
31. Cobine PA, Brady DC (2022). Cuproptosis: Cellular and molecular mechanisms un-derlying copper-induced cell death. Mol Cell, 82(10):1786-1787.
32. Ge EJ, Bush AI, Casini A, et al (2022). Con-necting copper and cancer: from transi-tion metal signalling to metalloplasia. Nat Rev Cancer, 22(2):102-113.
33. Kargozar S, Mozafari M, Ghodrat S, Fiume E, Baino F (2021). Copper-containing bi-oactive glasses and glass-ceramics: From tissue regeneration to cancer therapeutic strategies. Mater Sci Eng C Mater Biol Appl, 121:111741.
34. Subbiah V, Shen T, Terzyan SS, et al (2021). Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann On-col, 32(2):261-268.
| Files | ||
| Issue | Vol 52 No 5 (2023) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijph.v52i5.12718 | |
| Keywords | ||
| Cuproptosis lncRNA Thyroid carcinoma Immunotherapy | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Cai Y, Niu B, Gao J, Su H. Potential Role of Cuproptosis-Related Lncrna in Prognosis and Immunotherapy of Thyroid Carcinoma. Iran J Public Health. 2023;52(5):995-1007.
